TRVI Stock Forecast & Price Target

Trevi Therapeutics is a Buy-rated stock with a PT of $30 due to its strong IP, multiple potential blockbuster indications, and increasing enthusiasm among specialists. With Haduvio as its main asset and a strong cash runway until 2030, the company is well-positioned to generate positive clinical and commercial results in the near future. Recent market developments, such as GSK's failure in the same field, have increased Trevi's white space for both clinical and strategic success, further supporting the positive outlook. In addition, expert calls suggest a favorable setup for the company's upcoming earnings report, with potential for significant outperformance on top of already strong performance in its circuit. Finally, with a validated, de-risked epilepsy floor in its pipeline, OVID can also unlock new growth opportunities and create value for investors.

Trevi Therapeutics is facing several fundamental challenges, including the recent discontinuation of a similar drug for refractory chronic cough by a competitor as well as high risks for success in their clinical trials. Additionally, their valuation and current price target are not justified, with an 11.3% weighted average cost of capital and only an 80% probability of success for their IPF-CC treatment and a 70% probability for their RCC treatment. The company also faces significant risks such as competitive pressure, reimbursement uncertainty, and regulatory and trial risks, as well as potentially high capital requirements and operational dependence.